Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity
Satavaptan, a vasopressin V2 receptor antagonist, has been shown to improve the control of ascites in cirrhosis in short-term phase II studies. The aim of this study was to evaluate the efficacy and safety of satavaptan in three different populations of patients with cirrhosis and ascites.
Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity
Satavaptan, a vasopressin V2 receptor antagonist, has been shown to improve the control of ascites in cirrhosis in short-term phase II studies. The aim of this study was to evaluate the efficacy and safety of satavaptan in three different populations of patients with cirrhosis and ascites.
...more
More shows like Medizin - Open Access LMU - Teil 19/22